Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2023 Jun 10

PMID 37297749

Authors

Ana Maria Garcia-Munoz

Desiree Victoria-Montesinos

Begona Cerda

Pura Ballester

Eloisa Maria de Velasco

Pilar Zafrilla

Affiliations

Soon will be listed here.

Abstract

Background: The visibility of Rare Diseases is a new challenge for society. These diseases are numerous, heterogeneous in nature and distribution, characterized by a high mortality rate but low prevalence, and usually presenting a severe evolution. Adherence to medication studies in rare diseases are uncommon, due to treatment scarcity.

Objectives: The main purpose of this study is to do a meta-analysis, evaluating the level of adherence to medication in the most prevalent rare diseases.

Methods: This work is a systematic review, and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD42022372843) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Adherence to treatment in this systematic review and meta-analysis was collected from all studies included, based on the crude numerators and denominators reported, using either the Morisky Medication Adherence Scale 4 or -8.

Results: A total of 54 records were identified through database searches, or after screening relevant manuscripts' references. Finally, 18 studies were included in this systematic review and meta-analysis. A total of 1559 participants (54.18% women) aged less than 84 years old were included. Twelve studies used the MMAS-8. In 8 of them, they established the level of adherence to treatment in three categories (low, medium, and high), with the mean prevalence in each of them being 41.4%, 30.4%, and 28.2%, respectively.

Conclusions: The results observed in adherence to treatment in patients with rare diseases show great variability, due to the different aspects involved in the greater or lesser applicability of the medication.

Citing Articles

Development and validation of the Out-of-Hospital Adherence Questionnaire for Stroke Patients (OHAQ-SP).

Sun H, Wu M, Qu J, Lu J BMC Neurol. 2024; 24(1):460.

PMID: 39587529 PMC: 11590505. DOI: 10.1186/s12883-024-03962-z.

Effect of exercise-nutrition-psychology oriented nursing in patients undergoing interventional embolization for intracranial aneurysm.

Lin G, Long X Am J Transl Res. 2024; 16(1):333-341.

PMID: 38322562 PMC: 10839397.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Bacci E, Coyne K, Poon J, Harris L, Boscoe A . Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019; 19(1):335. PMC: 6925439. DOI: 10.1186/s12883-019-1573-2. View

Belzer L, Wright S, Goodwin E, Singh M, Carter B . Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action. Children (Basel). 2022; 9(7). PMC: 9325007. DOI: 10.3390/children9070933. View

Fogarty H, Gaul A, Syed S, Aleksejenko N, Geoghegan R, Conroy H . Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. Ir J Med Sci. 2021; 191(2):809-816. PMC: 8983545. DOI: 10.1007/s11845-021-02588-1. View

Pernell B, DeBaun M, Becker K, Rodeghier M, Bryant V, Cronin R . Improving Medication Adherence with Two-way Short Message Service Reminders in Sickle Cell Disease and Asthma. A feasibility randomized controlled trial. Appl Clin Inform. 2017; 8(2):541-559. PMC: 6241750. DOI: 10.4338/ACI-2016-12-RA-0203. View

Mongkhon P, Ashcroft D, Scholfield C, Kongkaew C . Hospital admissions associated with medication non-adherence: a systematic review of prospective observational studies. BMJ Qual Saf. 2018; 27(11):902-914. DOI: 10.1136/bmjqs-2017-007453. View

Jacquelet E, Poujois A, Pheulpin M, Demain A, Tinant N, Gastellier N . Adherence to treatment, a challenge even in treatable metabolic rare diseases: A cross sectional study of Wilson's disease. J Inherit Metab Dis. 2021; 44(6):1481-1488. DOI: 10.1002/jimd.12430. View

Viola A, Drachtman R, Kaveney A, Sridharan A, Savage B, Delnevo C . Feasibility of Medical Student Mentors to Improve Transition in Sickle Cell Disease. J Pediatr Psychol. 2021; 46(6):650-661. PMC: 8291672. DOI: 10.1093/jpepsy/jsab031. View

Galadanci N, Abdullahi S, Vance L, Tabari A, Ali S, Belonwu R . Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017; 92(8):780-788. PMC: 5523858. DOI: 10.1002/ajh.24770. View

10.

Macdonald M, Martin-Misener R, Helwig M, Smith L, Godfrey C, Curran J . Experiences of adults with cystic fibrosis in adhering to medication regimens: a qualitative systematic review. JBI Database System Rev Implement Rep. 2016; 14(5):258-85. DOI: 10.11124/JBISRIR-2016-002362. View

11.

Galadanci N, Abdullahi S, Tabari M, Abubakar S, Belonwu R, Salihu A . Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Pediatr Blood Cancer. 2014; 62(3):395-401. PMC: 4304992. DOI: 10.1002/pbc.25289. View

12.

Badawy S, Thompson A, Lai J, Penedo F, Rychlik K, Liem R . Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016; 64(6). DOI: 10.1002/pbc.26369. View

13.

Knudsen K, Pressler T, Mortensen L, Jarden M, Skov M, Quittner A . Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. Springerplus. 2016; 5(1):1216. PMC: 4967055. DOI: 10.1186/s40064-016-2862-5. View

14.

Maselbas W, Czlonkowska A, Litwin T, Niewada M . Persistence with treatment for Wilson disease: a retrospective study. BMC Neurol. 2019; 19(1):278. PMC: 6849180. DOI: 10.1186/s12883-019-1502-4. View

15.

Pereira E, Cavalcante A . Prescription is not enough: the importance of adherence to pharmacological treatment of COPD. J Bras Pneumol. 2022; 48(1):e20220058. PMC: 8964105. DOI: 10.36416/1806-3756/e20220058. View

16.

Kleinsinger F . The Unmet Challenge of Medication Nonadherence. Perm J. 2018; 22:18-033. PMC: 6045499. DOI: 10.7812/TPP/18-033. View

17.

Adebiyi M, Manalo J, Xia Y . Metabolomic and molecular insights into sickle cell disease and innovative therapies. Blood Adv. 2019; 3(8):1347-1355. PMC: 6482357. DOI: 10.1182/bloodadvances.2018030619. View

18.

Badawy S, Thompson A, Penedo F, Lai J, Rychlik K, Liem R . Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017; 98(6):608-614. DOI: 10.1111/ejh.12878. View

19.

Gimenez-Lozano C, Paramo-Rodriguez L, Cavero-Carbonell C, Corpas-Burgos F, Lopez-Maside A, Guardiola-Vilarroig S . Rare Diseases: Needs and Impact for Patients and Families: A Cross-Sectional Study in the Valencian Region, Spain. Int J Environ Res Public Health. 2022; 19(16). PMC: 9408677. DOI: 10.3390/ijerph191610366. View

20.

Guptill J, Soni M, Meriggioli M . Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2015; 13(1):118-31. PMC: 4720661. DOI: 10.1007/s13311-015-0398-y. View